It is provided the first virtual implementation of an ongoing rhythm-guided OAC trial, showing that pill-in-pocket OAC may lower bleeding risk compared to continuous OAC, highlighting the potential of virtual clinical trials to guide clinical trial design.
Abstract
Abstract Background: Oral anticoagulation (OAC) reduces stroke risk in patients with atrial fibrillation (AF), and screening can enable earlier AF detection and OAC initiation. However, the population-level trade-off between stroke prevention and OAC-related major bleeding for different types of AF and OAC therapy remains uncertain, and large randomized trials to resolve this are costly and time-consuming. Methods: A state-transition Markov-like model was developed to: 1) simulate the lifetime course of AF, stroke, major bleeding, and death in different virtual populations; 2) quantify benefits (stroke reduction) and harms (major bleeding) of systematic AF screening with screening-triggered OAC across CHA2DS2-VA scores; and 3) compare rhythm-guided, time-delimited ("pill-in-pocket") OAC with continuous OAC. Results: The model synthesized information from multiple clinical sources and reproduced stroke and bleeding incidence across clinical scenarios. At CHA?DS?-VA=2, long-term continuous rhythm monitoring (LT-CRM) with OAC lowered stroke risk (HR, 0.92 [95%CI, 0.88-0.96]) but raised bleeding risk (HR, 1.17 [95%CI, 1.07-1.27]) versus no screening. Time-to-benefit was shorter than time-to-harm for CHA?DS?-VA?4, but longer for CHA?DS?-VA=0. Pill-in-pocket OAC vs continuous OAC showed no difference in stroke/mortality (HR, 1.03, 95%CI [0.91-1.16]) but lower bleeding risk (HR, 0.81, 95%CI: 0.68-0.96]) in patients with elevated bleeding risk, but not at baseline. Sensitivity analyses revealed that the risk-benefit profiles of screening or pill-in-pocket OAC strategy further depend on OAC adherence and bleeding risks. Conclusions: Our model highlights a trade-off between stroke reduction and bleeding for systematic screening-initiated OAC, with net benefit for CHA?DS?-VA?4. We provide the first virtual implementation of an ongoing rhythm-guided OAC trial, showing that pill-in-pocket OAC may lower bleeding risk compared to continuous OAC, highlighting the potential of virtual clinical trials to guide clinical trial design.
BACKGROUND
Discontinuation of oral anticoagulant (OAC) in patients without recurrent atrial arrhythmia after ablation for atrial fibrillation (AF) has been demonstrated to reduce composite outcomes of stroke, systemic embolism, and major bleeding compared with continued OAC.
OBJECTIVE
This study aimed to evaluate the...
Young-Shin Lee, J. Uhm, Junbeom Park et al.· Heart Rhythm· 0 citations
Current guidelines recommend individual oral anticoagulant (OAC) decision after catheter ablation for atrial fibrillation (AF) based on stroke risk. However, recent randomized trials suggest that OAC discontinuation following successful ablation may be feasible in selected patients. Real-world evidence on the net...
Y. Lee, P.-S. Yang, E. Jang et al.· European Heart Journal· 0 citations
Background:
Oral anticoagulation (OAC) reduces stroke risk in atrial fibrillation (AF), but major bleeding (MB) remains a concern. Current evidence on post-bleeding treatment patterns is limited.
Question:
How does bleeding influence OAC treatment patterns in the real-world?
Methods:
This retrospective s...
Mahmoud A. Hashim, E. O'Brien, A. Kang et al.· Circulation· 0 citations
The optimal duration of oral anticoagulation (OAC) after successful catheter ablation (CA) for atrial fibrillation (AF) remains controversial. Current guidelines recommend indefinite OAC based on stroke risk profiles, but long-term therapy adherence is suboptimal due to bleeding concerns. Recent randomized trials—ALONE...
Background Oral anticoagulation (OAC) in patients with atrial fibrillation (AF) reduces ischaemic stroke (IS), but increases bleeding, including intracranial haemorrhage (ICH). As catheter ablation reduces AF burden and IS risk, we evaluated the net clinical benefit (NCB) of continuing versus discontinuing OAC after AF...
S. Koolaji, Diana A. Gorog, J. Leader et al.· Thrombosis and Haemostasis· 0 citations
Atrial fibrillation (AF) is a leading, modifiable risk factor for ischaemic stroke, with 20–30% of stroke patients harbouring underlying AF. Management of AF, however, differs substantially depending on clinical context. In ischaemic stroke patients with pre-known AF, direct oral anticoagulants (DOACs) are the cornerst...
K. Wasser, Deborah Bochert, J. Leyhe et al.· Neurological Research and Pr...· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.